CCL2 and gastric cancer: Based on public omics data, it was also found that some of these biomarkers showed significant changes in the progression from gastritis to dysplasia and gastric cancer (Fig. 3C), and were reported to participant in the progression of gastric cancer, such as LEP, CCL2, CD14 and TNF.